AstraZeneca Pharma India Limited has announced the final voting results of its 47th Annual General Meeting (AGM) held on August 10, 2026. The Scrutinizer’s Report, dated August 11, 2026, and signed by Mr. Vijayakrishna K T, confirms that all five resolutions placed before shareholders were duly passed with the requisite majority.

The meeting, conducted via Video Conferencing and Other Audio Visual Means (VC/OAVM), commenced at 3:18 p.m. after establishing a quorum and concluded at 5:20 p.m. Shareholders exercised their voting rights through remote e-voting from August 6, 2026, to August 9, 2026, and via e-voting during the meeting. A total of 29,932 shareholders were on record as of August 3, 2026. Of these, 42 shareholders attended the meeting through VC/OAVM (one promoter and 41 public), while no shareholders attended in person or through proxy.

Voting Results by Resolution

The promoter group, holding 18.75 million shares (75% of the total equity), voted in favor of 100% of their shares for all five resolutions. Public institutional investors also showed strong support, particularly for the financial statements and dividend declarations.

Key Voting Details

Financial Statements and Dividend: The adoption of the audited financial statements for FY26 and the declaration of a dividend of ₹36 per equity share received unanimous support from promoters and public institutions. Among public non-institutional shareholders, there were only four votes against the financial statements and four against the dividend, representing negligible dissent.

Director Appointments: Ms. Bhavana Agrawal (DIN: 10485441), who retires by rotation, was reappointed as a director. She received 99.97% of the votes polled in her favor. Dissent came primarily from public non-institutional shareholders, who cast 704 votes against her reappointment out of 769,006 polled.

Ms. Shilpa Divekar Nirula (DIN: 06619353) was reappointed as an Independent Director for a second term from December 29, 2026, to December 28, 2031. This special resolution received 98.22% support. Public institutional shareholders showed higher dissent here compared to other resolutions, with 386,356 votes against (17.03% of their polled votes) compared to 1,882,419 votes in favor.

Statutory Auditors: The appointment of BSR & Co. LLP (FRN: 101248W/W-00022) as statutory auditors was approved with 99.99% of votes in favor. Only 799 votes were cast against this resolution, all from public non-institutional shareholders.

Compliance and Regulatory Filings

The proceedings were conducted in accordance with Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has informed the Bombay Stock Exchange and the National Stock Exchange of India Limited regarding the summary of proceedings and the final voting results.

The Scrutinizer, Mr. Vijayakrishna K T (FCS No. 1788, CP No. 980), certified that the e-voting facility provided by National Securities Depository Limited (NSDL) was conducted fairly and transparently. The company secretary, Tanya Sanish, confirmed the compliance with Regulation 44(3) of the SEBI LODR Regulations, 2015.

AstraZeneca Pharma India Limited reported a robust 30% year-on-year revenue growth to ₹6,828 million in Q1FY27, driven by strong momentum across its core therapy areas of Oncology, Biopharmaceuticals, and Rare Disease. Despite the top-line expansion, net profit after tax (PAT) declined to ₹379.3 million from ₹558.3 million in Q1FY26, reflecting significant margin compression. The Board of Directors approved the unaudited financial results on August 10, 2026, alongside key leadership changes including the appointment of Arun Krishna as an Additional Director.

Revenue Growth Contrasts with Profit Decline

The company’s total revenue from operations rose to ₹6,827.9 million in the quarter ended June 30, 2026, compared to ₹5,263.1 million in the corresponding period last year. This growth was underpinned by a 26% increase in Oncology revenue to ₹4,649 million and a 36% surge in Biopharmaceuticals (CVRM, R&I, and V&I) to ₹1,619 million. Rare Disease revenues also saw substantial expansion, growing 35 times to ₹144 million.

However, profitability metrics faced headwinds. EBITDA fell sharply to ₹489 million (estimated from PBT and expenses) with margins contracting significantly. The profit before exceptional items and tax stood at ₹509.9 million, down from ₹750.6 million YoY. After accounting for exceptional items related to the closure of the Bangalore manufacturing site (₹2.4 million) and tax expenses of ₹128.2 million, PAT settled at ₹379.3 million.

Key Financial Metrics

Leadership Changes and Strategic Initiatives

The Board approved the appointment of Arun Krishna as an Additional Director (Non-Executive) effective August 17, 2026. Krishna, currently Asia Area Vice President at AstraZeneca, oversees operations for nine markets including India. Additionally, Bhavana Agrawal’s designation will change from Executive Director to Non-Executive Director effective September 1, 2026, following her transition to a regional role within the AstraZeneca Group.

Strategically, the company advanced several initiatives, including regulatory approvals for acalabrutinib in combination therapies for CLL/SLL and MCL, and trastuzumab deruxtecan for HER2-positive breast cancer. AstraZeneca also signed an MoU with the Government of Telangana to deploy AI-enabled lung cancer screening across 20 public health facilities using Qure.ai’s technology.

What the Numbers Show

The divergence between revenue growth (+30%) and profit decline (-32%) highlights intense cost pressures or aggressive investment in sales and marketing to support new product launches. While Oncology remains the dominant revenue driver, the sharp contraction in PAT suggests that operating leverage has not yet materialized despite higher volumes. The company’s focus on high-growth niche areas like Rare Disease and strategic partnerships in AI-driven diagnostics indicates a long-term value creation strategy, albeit with short-term earnings volatility.